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Serotonin, neural markers, and
memory
Alfredo Meneses*
Departamento de Farmacobiología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional,
Mexico City, Mexico
Diverse neuropsychiatric disorders present dysfunctional memory and no effective
treatment exits for them; likely as result of the absence of neural markers associated
to memory. Neurotransmitter systems and signaling pathways have been implicated
in memory and dysfunctional memory; however, their role is poorly understood.
Hence, neural markers and cerebral functions and dysfunctions are revised. To our
knowledge no previous systematic works have been published addressing these
issues. The interactions among behavioral tasks, control groups and molecular changes
and/or pharmacological effects are mentioned. Neurotransmitter receptors and signaling
pathways, during normal and abnormally functioning memory with an emphasis on
the behavioral aspects of memory are revised. With focus on serotonin, since as
it is a well characterized neurotransmitter, with multiple pharmacological tools, and
well characterized downstream signaling in mammals’ species. 5-HT1A, 5-HT4, 5-HT5,
5-HT6, and 5-HT7 receptors as well as SERT (serotonin transporter) seem to be
useful neural markers and/or therapeutic targets. Certainly, if the mentioned evidence is
replicated, then the translatability from preclinical and clinical studies to neural changes
might be confirmed. Hypothesis and theories might provide appropriate limits and
perspectives of evidence.
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Introduction
It should noted that while, memory formation and forgetting are functions of the brain (e.g.,
Fioravanti and Di Cesare, 1992; Wagner and Davachi, 2001; Wixted, 2004; Mansuy, 2005;
Hardt et al., 2013; Hupbach, 2013; Callaghan et al., 2014; Li et al., 2015a); in contrast, diverse
neuropsychiatric disorders present dysfunctional memory (Meyer-Lindenberg et al., 2012; Millan
et al., 2012, 2014). AD is popular brain alteration presenting memory deficits and dementia and
the leading cause of dementia, and a major public health priority; but dysfunctional memory is
observed in other age-related neurodegenerative disorders, schizophrenia, post-traumatic stress
disorder, strokes, etc. (Millan et al., 2014; Hashimoto, 2015). Certainly, no effective treatment for
dysfunctional memory exists (e.g., Millan et al., 2012, 2014; Sun et al., 2015); likely due to the
absence of neural markers associated to memory. Hence, memory, amnesia, forgetting (e.g., Tellez
et al., 2012b) and AD (e.g., McConathy and Sheline, 2015; Muenchhoff et al., 2015; also Scarr et al.,
2015) as well as mild cognitive impairment (MCI) (Eshkoor et al., 2015) require neural markers.
Certainly, AD is a very complex neuropsychiatric disorder, where memory becomes
progressively dysfunctional (e.g., Solodkin and van Hoesen, 1997; Rodríguez et al., 2012) resulting
in amnesia and dementia. In contrast, forgetting is unintentional process characterized as a failure
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to remember information or a rather strategic function of
the brain that helps to reduce interference in the processing
or retrieval of relevant information (Ludowiq et al., 2010).
Likewise, forgetting as a physiological phenomenon occurs all
the time (see McGaugh, 2013; see also Davis, 2010; Berry et al.,
2012; Hardt et al., 2013; Kaku et al., 2013; Li and Richardson,
2013; Papenberg et al., 2013). However, the pharmacological
and neuroanatomical bases of forgetting or memory have been
little explored and as diverse neuropsychiatric disorders present
dysfunctional memory, we are aiming potential neural markers.
For instance, phrasing neural markers and brain functions in
PubMed (May 7, 21 and 29 or June 2, 2015) yield 318 or 319
(including 50 review papers) publications. Hence, herein, aiming
clues about mapping neural markers link to cerebral functions
and dysfunctions. Mainly memory formation, dysfunctional
memory, and as forgetting, which has been little explored respect
to neural markers. In spite of promissory findings, to our
knowledge, no previous systematic works have been published
addressing these issues. It should be noted that of the revised
papers, several are rich in backgrounds and perspectives.
Examples illustrating the interaction among behavioral
tasks (Box 1), control groups and molecular changes and/or
pharmacological effects are mentioned in the following lines.
Importantly, behavioral parameters, drug-treatment and
cognitive processes interact in mammals (see below) and
invertebrate species (e.g., Chen et al., 2014). Particularly the role
of serotonin in memory: interactions with neurotransmitters and
downstream signaling might be useful (e.g., Seyedabadi et al.,
2014; Eskenazi et al., 2015). Although the focus herein are adult
mammal animals; notwithstanding, important recent advances
in invertebrate species, include Monje et al. (2013) reporting that
flotillin-1 is an evolutionary-conserved memory-related protein
up-regulated in implicit and explicit learning paradigms; thus,
translational approach—from invertebrates to rodents—led to
the identification of flotillin-1 as an evolutionary-conserved
memory-related protein.
Actually, serotonin has pharmacological tools and well
characterized downstream signaling in mammals’ species
(e.g., Marin et al., 2012; Borroto-Escuela et al., 2015; McCorvy
and Roth, 2015); then serotonin and other neural markers
are used for studying cerebral functions and dysfunctions
(e.g., Tomie et al., 2003; Wellman et al., 2007; Cavallaro, 2008;
Marcos et al., 2008; Da Silva Costa-Aze et al., 2012; Ménard
and Quirion, 2012; Reichel et al., 2012; Rodríguez et al., 2012;
Woods et al., 2012; Haahr et al., 2013; Alabdali et al., 2014;
Freret et al., 2014; Kitamura et al., 2014; Kondo et al., 2014;
Lecoutey et al., 2014; Leger et al., 2014; Seyedabadi et al., 2014;
Leiser et al., 2015; Suzuki and Lucas, 2015; Westrich et al.,
2015; Zilles et al., 2015). Evidence is organized according with
5-HT markers (i.e., receptors and transporter) but markers of
other neurotransmission systems are included. Importantly,
using well-established 5-HT neural markers (Blenau and
Baumann, 2015; Lau et al., 2015; Müller and Homberg, 2015)
might provide insights about known and novel markers and
therapeutic targets. Müller and Homberg (2015) are providing
an excellent analysis regarding 5-HT markers, drug use and
addiction.
Memory Tasks and Molecular Changes
Memory Decline across Aging
Ménard and Quirion (2012) using the Morris Water Maze
(MWM) task, distinguish aged rats in two groups—memory-
impaired (AI) and memory-unimpaired (AU) relative to 6-
months old adult animals. Dysfunctional memory was associated
to increased metabotropic glutamate receptors 5 (mGluR5) in
hippocampal post-synaptic densities (PSD) (Table 1); Ménard
and Quirion (2012) conclude that in successful cognitive aging
(i.e., AU animals) present a critical role for mGluR5, Homer 1
proteins and downstream signaling pathways. Certainly, in terms
of signaling respect to cognition-enhancing drug targets, insights
are emerging (e.g., Seyedabadi et al., 2014; Gyurko et al., 2015;
Ménard et al., 2015; Sun et al., 2015).
Autism: Neuro-inflammation and
Neurotransmission Impairment
Although, Alabdali et al. (2014) did find that serotonin
or dopamine in platelet-free plasma not correlated with
social and cognitive dysfunction. It should be noted that
serotonin has multiple markers (see below). And, several
neurochemical parameters might show sensitivity and specificity;
thus contributing to earlier and more accurate diagnosis of
dysfunctional memory in disease such autism, AD, and the
identification of effective treatments (e.g., Sheline et al., 2014a,b;
Strac et al., 2015).
5-HT Systems
As already mentioned, serotonin (5-hydroxytryptamine, 5-HT)
is one of the neurotransmitter well characterized in mammal
species (e.g., Hoyer et al., 1994; Saulin et al., 2012; Borroto-
Escuela et al., 2015; McCorvy and Roth, 2015), it has multiple
neural markers, including receptors (i.e., 5-HT1A/1B/1D, 5-
HT2A/2B/2C, 5-HT3, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors)
and transporter (named SERT) as well as volume transmission.
These 5-HT markers are present in brain areas involved in
memory (e.g., Buhot et al., 2003a,b; Puig and Gulledge, 2011;
Rodríguez et al., 2012; Barlow et al., 2015; Leiser et al., 2015),
sentence compression (Zilles et al., 2015) and drug addiction
(Müller and Homberg, 2015).
Serotonergic Gene Regulation during Learning
and Memory
In an elegant work, Cavallaro (2008) using DNA microarrays
analyzed hippocampal 5-HT receptors in two behavioral memory
tasks and different times (Table 2); observing differential
expressions in 12 receptors (Htr1a, Htr1b, Htr1d, Htr1f, Htr2a,
Htr2c, Htr3a, Htr4, Htr5a, Htr5b, Htr6, and Htr7). At least
Htr2c, Htr3a and Htr6 receptors had significant changes relative
to swimming control animals and water maze trained animals.
Htr2c expression was reduced at 1 h and increased at 24 h
following training. Htr3a-mRNA was increased at 24 h, whereas
Htr6 was decreased at 6 h; as observed in autoshaping (see
below). In passive avoidance task, three 5-HT receptors showed
changes in expression respect to naive and trained animals (i.e.,
conditioned animals, CA). Indeed, the expression of Htr3a was
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increased, whereas those of Htr1b and Htr4 were decreased.
Certainly, expression of 5-HT receptors were also observed in
control groups subjected to physical activity and mild stress
(naive vs. swimming controls in the water maze; naive vs. CSTA
and USTA in passive avoidance); notwithstanding, memory
consolidation produced different magnitudes (e.g., Htr2c in the
water maze) often opposite trends than in control animals (e.g.,
Htr3a in both water maze and passive avoidance). Producing
cumulative patterns of gene expression, associated to time
and 5-HT subtype receptor (see Cavallaro, 2008). Importantly,
apparently water maze memory requires slight 5-HT7 receptor
expression within 1-h; and passive avoidance memory involves
expression of 5-HT1A−1F, 5-HT2A, and 5-HT5A receptors. Of
course, remaining to determine if the suppression of the other 5-
HT receptors is necessary. Certainly, the molecular requirements
differ between water maze and passive avoidance.
TABLE 1 | Memory task and molecular changes: unimpaired vs. impaired






Brain area: hippocampal (CA1) Ménard and Quirion,
2012
Groups
AI -AI dysfunctional memory, ↑ in
hippocampal (CA1) mGluR5 in PSD
-Hippocampal up-regulated Homer 1a
and 1b/c levels PSD
AU -AU had enhanced mGluR5 as well as
Homer 1b/c stainings.
- AU had higher PKCc, ERK, p70S6K,
mTOR, and CREB activation.
- AU higher expression of immediate
early gene Arc/Arg3.1.
MWM, Morris Water Maze; Aging AU, memory unimpaired; aging impaired memory (IM),
PSD, post-synaptic densities.
Notably, Zaldivar and Krichmar (2013) observe in
behaviorally naïve (i.e., untrained) animals, neurotransmitters
changing including 5-HT receptors expression in areas
regarded to neuromodulation or memory (amygdala); revealing
connectivity and receptor localization, and patterns of expression
among neurotransmission systems, receptors and brain areas.
5-HT1A Receptor
Although 5-HT1A receptor may serve as a biomarker for
cognitive functioning and target for treatment of cognitive
impairment; notwithstanding hitherto evidence remains sparse
and inconsistent (Borg, 2008; Borg et al., 2009). Certainly,
the situation is changing; e.g., Yoshimi et al. (2014) report
that brexpiprazole, presents serotonin-dopamine activity, and
5-HT1A receptor partial agonism, attenuates phencyclidine-
induced cognitive deficits; an effect blocked by the selective
5-HT1A receptor antagonist WAY-100,635 (which alone has
no effect). Yoshimi et al. (2014) conclude that brexpiprazole
could ameliorate cognitive deficits in schizophrenia and other
neuropsychiatric diseases. Contrasting findings exist regarding
the 5-HT1A partial agonists (e.g., buspirone), which alone impair
memory in normal subjects (Meneses, 1999) but some of
them (e.g., tandospirone) might be useful in the treatment of
schizophrenia pathophysiology (Sumiyoshi et al., 2008). And,
as tandospirone (e.g., Baba et al., 2015) also has anti-amnesic
effects or facilitate performance in difficult memory tasks; hence,
5-HT1A partial agonists might be useful in the treatment of
dysfunctional memory.
Certainly, while if 5-HT1A receptor agonists, partial agonists,
or antagonists might be used for memory alterations (e.g.,
Meneses and Perez-Garcia, 2007; Pittalà et al., 2015); functional
selectivity or biased agonism is revealing important insights
regarding 5-HT1A and 5-HT3A receptors (e.g., Vardy and
Kenakin, 2014; McCorvy and Roth, 2015). For instance, van
Goethem et al. (2015) study “biased,” 5-HT1A receptor agonists
in a novel object pattern separation task (relative to episodic
memory); showing that by preferentially activating post-synaptic
TABLE 2 | 5-HT1A receptor.
Function/dysfunction Findings:






memory impairment and variations in expressione expressionc modulation of expressioni expression
recovery from dissociative
amnesia
increase of 5-HT1A receptor in cortical regions
g
object-location associations lower right than left hippocampal binding potential is
related to better memory performancej
Morris water maze memory
retrieval
expressionf
Tomie et al., 2003 a; Luna-Munguía et al., 2005 b; Cavallaro, 2008 c; Perez-Garcia and Meneses, 2009 d ; Li et al., 2015b d ; Saroja et al., 2014 f ; Kitamura et al., 2014 g; Baas and
Heitland, 2014 h; Sase et al., 2015i ; Glikmann-Johnston et al., 2015 j .
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5-HT1B receptor KO Exhibit a task-dependent selective learning facilitation; indeed, selective facilitation/impairment
depending on the cognitive demand and/or age-related decline in spatial learning (water maze) abilities
Buhot et al., 2003a,b; Wolff
et al., 2003
Aggressive social model High 5-HT1B receptor density in the BLA to predict high levels of aggression in observer rats Suzuki and Lucas, 2015
Expression Positive correlations in control subjects between creative ability and average 5-HT1B receptor availability
in gray matter
Varrone et al., 2015
BLA, basolateral amygdala.
5-HT1A heteroreceptors, or raphe-nuclei autoreceptors are
potential novel molecular targets for improving memory.
Likewise, Stroth et al. (2015) report that arylpiperazine ligands
of 5-HT1A receptor preferentially affect cAMP signaling vs. β-
arrestin-2 recruitment; proposing the development of signaling
pathway-selective drugs targeting this receptor.
Notably, recovery from dissociative amnesia increases cortical
5-HT1A receptor (Kitamura et al., 2014; Table 3). Likewise,
memory in autoshaping task (see Box 2) also increases 5-HT1A
receptor expression in 14 brain areas, but decrements in 7
and no changes in 12 (Table 3); suggesting that upregulated,
down-regulated, and “silence” 5-HT1A receptor in brain areas
form part of neural circuits engaged in memory formation; thus
demonstrating a high degree of specificity andmemory mapping.
Importantly, Glikmann-Johnston et al. (2015) report that
hippocampal human asymmetry in 5-HT1A receptor expression
(using [18F] MPPF binding), accompanies memory for object-
location associations; lower right than left hippocampal binding
potential is related to better memory performance (Table 2).
Aubert et al. (2013) also report that the dual 5-HT1A/7 receptor
agonist 8-OH-DPAT increased transcription of adenylate cyclase
1 in the hippocampus (CA1), suggesting that memory function
could play a role in altered pairmate interaction dynamics;
and these changes might be caused by 8-OH-DPAT-induced
up- or down-regulation of 5-HT1A and 5-HT7 receptor in
the medial prefrontal cortex and in the hippocampus (CA1),
respectively; and according with Aubert et al. (2013); and
such as hypothesis is supported by rodent studies that
implicate 5-HT7 function in contextual learning and memory
consolidation.
On the other hand, genetic variability within 5-HT1A receptor
(rs6295) is associated with contextual fear independent (Table 3)
(Baas and Heitland, 2014). Likewise, Weber et al. (2015)
report that conditional inactivation of the GLUA1-encoding
Gria1 gene selectively in 5-HT neurons of adult mice (i.e.,
Gria1 5-HT-/- mice) exhibited a distinct anxiety phenotype but
showed no alterations in locomotion, depression-like behavior, or
learning andmemory. Importantly, contextual fear task increases
hippocampal AMPA-, GluN1- and 5-HT1A− containing receptor
complexes (Sase et al., 2015) (Table 3). In addition, Saroja
et al. (2014) studied spatial memory retrieval and hippocampal
monoamine receptor (MAR) complexes (including 5-HT1A and
5-HT7 receptors, and dopamine D1 and D2 receptors and
colocalizations) in mice of 3–12 and 18 months. D1, D2, and
5-HT7 containing receptor complex levels were decreasing with
age while 5-HT1A receptor-containing complex was increased.
In addition, the time spent in the target quadrant (i.e., memory
retrieval) correlated with D1, 5-HT7, and 5-HT1A receptors
complex expression. Saroja et al. (2014) conclude that individual
monoamine receptors are linked to spatial memory retrieval
and are modulated by age. This same group (Subramaniyan
et al., 2015) reports that the receptor complex levels containing
hippocampal GluN1 and GluN2A of NMDARs, GluA1 and
GluA2 of AMPA receptors, nAch7 and the D1A dopamine
receptors were elevated during spatial learning, whilst levels of
GluA3 and 5-HT1A receptor containing complexes were reduced.
Thus, supporting that 5-HT1A receptor is useful neurobiological
marker of memory.
Pavlovian Autoshaping: 5-HT1A and 5-HT2
Receptors (Binding Sites)
Interestingly, Tomie et al. (2003), studied the effects of experience
with Pavlovian autoshaping procedures (Box 2) on lever-press
conditioned response (CR) performance and 3H-8-OH-DPAT-
labeled binding of 5-HT1A and probably 5-HT7 (it should be
noted that this drug has affinity for 5-HT7, see below; Table 3);
as well as 125I-LSD-labeled binding of 5-HT2A receptors were
evaluated in four groups of rats. The groups (Paired High CR
and Paired Low CR) received Pavlovian autoshaping procedures
wherein the presentation of a lever (conditioned stimulus,
CS) was followed by the response-independent presentation
of food (unconditioned stimulus, US). Group Paired High
CR showed more rapid CR acquisition and higher asymptotic
levels of lever-press autoshaping CR performance relative to
Group Low CR. Group Omission received autoshaping with
an omission contingency, such that performing the lever-press
autoshaping CR resulted in the cancelation the food US, while
Group Random received presentations of lever CS and food
US randomly with respect to one another. Though Groups
Omission and Random did not differ in lever-press autoshaping
CR performance, Group Omission showed significantly lower
levels of 5-HT1A binding in post-synaptic areas (frontal cortex,
septum, caudate putamen), as well as significantly higher plasma
corticosterone levels than Group Random. In addition, Group
Random showed higher levels of 5-HT1A binding in pre-synaptic
somatodendritic autoreceptors on dorsal raphe nucleus relative
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to the other three groups. Autoradiographic analysis of 5-HT2A
receptor binding revealed no significant differences between
Groups Paired High CR and Paired Low CR or between Groups
Omission and Random in any brain regions. Notably, although
extensive Pavlovian autoshaping training (Tomie et al., 2003)
failed to produce any correlation between 5-HT1A or 5-HT2A
receptor expression and CR; however, regardless the number of
CR, Tomie et al. (2003) demonstrated correlation between both
receptors expression and paired CS–US presentations. These data
are also indicating that the neuroanatomical, neurochemical,
and behavioral basis of Pavlovian and Pavlovian/Instrumental
Autoshaping (P/I-A) are different (see Box 2). Although the
latter could be considered as an instance of system processing
styles (i.e., S-S, S-R, and stimulus-reinforcer [S-Rf] learning;
see White and McDonald, 2002); nevertheless, the association
of CR and 5-HT markers (Tomie et al., 2003) is replicated
(Pérez-García et al., 2006; Pérez-García and Meneses, 2008).
Notably, similar associations are observed in the Morris Water
Maze and passive avoidance tasks (Cavallaro, 2008). Hence, the
evidence supports the notion that 5-HT1A receptor provides
diverse neurobiological markers, pharmacological and genetic
tools that have been used to investigate a variety of functions and
dysfunctions (for references Meneses and Liy-Salmeron, 2012).
Likewise, 5-HT1A receptor also is therapeutic target, it seems to
be useful for detecting functional and dysfunctional memory,
and co-expression with other neurotransmission systems and
serotonergic receptors.
5-HT1B/1D Receptor
The Buhot et al. (2003a,b; Wolff et al., 2003) seminal work (see
also Drago et al., 2010) showed that 5-HT1B receptor knockout
mice exhibit a task-dependent selective learning facilitation;
depending on the cognitive demand and/or age-related decline of
spatial learning abilities (Table 4). In addition, pharmacological
evidence indicates a possible involvement of hippocampal
CA1 5-HT1B/1D and 5-HT2A/2B/2C receptors in harmaline-
induced amnesia (Nasehi et al., 2014a). And 5-HT1B receptor
activation disrupts delayed alternation (DAL) performance in
mice (Woehrle et al., 2013) and chronic fluoxetine pretreatment
blocks 5-HT1B receptor- induced deficits; suggesting a 5-
HT1B receptor modulation in orbitofrontal-dependent DAL.
The 5-HT1B-induced DAL deficits may provide a model for
obsessive compulsive disorder (OCD; Woehrle et al., 2013).
The above evidence is consistent with the possibility that 5-
HT1B receptor inverse agonists might be useful for reversing
memory deficits (e.g., Meneses, 2001; Meneses and Tellez, 2015).
Importantly, 5-HT1B/1D receptor expression in the frontal cortex
is correlated to memory impairment (Garcia-Alloza et al., 2004).
Certainly, Drago et al. (2010) highlight that 5-HT1B receptor
is a candidate modulator of the mnemonic and motivationally
related symptoms in psychiatric illnesses. Moreover, positive
correlations exist between creative ability and 5-HT1B receptor
expression in gray matter of control subjects; as well as in
Parkinson disease (PD) patients between depression and creative
ability (Varrone et al., 2015); importantly, PD patients have
poor semantic memory and creative ability (Varrone et al.,
2015).
Neurobiological Mechanisms in the
Observational Learning of Aggression
Suzuki and Lucas (2015) report that chronic passive exposure
to aggression modifies expression of D2 receptor in the
nucleus accumbens core (AcbC) and shell (AcbSh), and 5-
HT1B receptor in the medial (MeA), basomedial (BMA), and
basolateral (BLA) amygdala. And increased aggressive behavior
reduced D2 receptor in bilateral AcbSh. Likewise, regardless
of exposure aggression length 5-HT1B receptor was augmented
in bilateral BLA. Finally, low D2 receptor expression in the
AcbSh significantly interacted with high 5-HT1B receptor density
in the BLA, predicting high levels of aggression in observer
animals (Table 4). Suzuki and Lucas (2015) conclude that the
dopamine-serotonin or AcbSh-BLA interactions; may be risk
factors for aggression in observers chronically witness aggressive
interactions (Suzuki and Lucas, 2015). Clearly, 5-HT1B receptor
expression was useful in detecting learning and memory of
aggression.
5-HT2A/2B/2C Receptors
Li et al. (2015a) report that 5-HT2A receptor is highly
expressed in the medial septum-diagonal band of Broca complex
(MS-DB), especially in parvalbumin (PV)-positive neurons
linked to hippocampal theta rhythm (involved in normal
and dysfunctional memory of PD). The medial forebrain
bundle (MFB) lesions impaired working memory, hippocampal
theta, decreased firing rate and density of MS-DB PV-
positive neurons, rhythm, and DA levels in septohippocampal
system and medial prefrontal cortex (mPFC). Intra-MS-
DB injection of the 5-HT2A receptor agonist 4-Bromo-3,6-
dimethoxybenzocyclobuten-1-yl) methylamine hydrobromide
(TCB-2) enhanced working memory, producing the opposite
effects in control and lesioned and shortening TCB-effects;
implicating dysfunctional 5-HT2A receptor. Li et al. (2015a)
conclude that unilateral lesions of the MFB induced working
memory deficit, and activation of MS-DB 5-HT2A receptor
enhanced working memory, and involve monoamine levels
in the hippocampus and mPFC. In addition, in a controlled
cross-over PET study using a delayed match-to-sample task
and the 5-HT2A receptor antagonist [18F] altanserin, Hautzel
et al. (2011) report a cognition-induced modulation of serotonin
in the orbitofrontal cortex (OFC). Importantly, Tomie et al.
(2003) demonstrated an association between 5-HT2A receptor
expression and memory formation in Pavlovian autoshaping
task. In addition, individual differences in impulsive action
and 5-HT2A receptor cortical variations have been noted (Fink
et al., 2015). Also, D2 and 5-HT2A receptors present genetic
variants and modulate physiological prefrontal cortex efficiency
during working memory and response to antipsychotics (Blasi
et al., 2015). Moreover, although an association between 5-HT2A
receptor polymorphism (his452tyr) and memory performances
in AD has been proposed; no differences in verbal memory were
identified by Guglielmi et al. (2015).
Importantly, Barlow et al. (2015) report markers of
serotonergic function in the orbitofrontal cortex and dorsal
raphé nucleus predicting individual variation in spatial-
discrimination serial reversal learning. These authors conclude
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TABLE 4 | 5HT 2A/2B/2C receptor.
Function/dysfunction Findings References
Parkinson disease MS-DB 5-HT2A receptor activation enhanced WM, which may be due to changes in the
activity of septohippocampal network and monoamine levels in the hippocampus and mPFC
Li et al., 2015a
Memory (match-to-sample task) Cognition-induced modulation of serotonin in the OFC: PET study of 5-HT2A Hautzel et al., 2011
Memory (Pavlovian autoshaping) 5-HT2Aexpression and CR(Pavlovian autoshaping) association Tomie et al., 2003
Spatial-discrimination serial reversal learning Individual variations of 5-HT2A in the OFC and dorsal raphé nucleus Barlow et al., 2015
Dopamine2 and 5-HT2A receptor variants DRD2 and HTR2A genetic variants together modulate physiological prefrontal efficiency during
working memory and also modulate the response to antipsychotics
Blasi et al., 2015
Fmr1 KO mice (model of fragile X syndrome); Combinations of 5-HT2B or D1-Rs
or 5HT2A or D2-Rs (low doses)
Enhance Ras-PI3K/PKB signaling input,
GluA1-dependent synaptic plasticity and learning in Fmr1
KO mice; without causing anxiety related side effects
Lim et al., 2014
5-HT2B receptor expression Htr2B
−/− mice, as shown by deficits in sensorimotor gating, in selective attention, in social
interactions and in learning and memory processes
Pitychoutis et al.,
2015
Against epilepsy induced memory decline Combined action at MT1/2 and 5HT2C receptors, reduced the depolarization-evoked release
of glutamate, strong neuroprotective action and possible antioxidant properties of agomelatine
Vimala et al., 2014
Chronic microwave-induced cognitive deficit Variations of 5-HT1A and 5-HT2C receptors expressions Li et al., 2015b
WM, working memory; OFC, orbitofrontal cortex; mPFC, medial prefrontal cortex; CR, conditioned responses; MT, melatonin.
that rats in the upper quintile of the distribution of perseverative
responses during repeated S-R reversals have significantly
reduced levels of the 5-HT metabolite, 5-hydroxy-indoleacetic
acid, in the OFC. Additionally, 5-HT2A receptor expression
in the OFC of mid- and high-quintile rats was significantly
reduced compared with rats in the low-quintile group. These
perturbations were accompanied by an increase in the expression
of monoamine oxidase-A (MAO-A) and MAO-B in the lateral
OFC and by a decrease in the expression of MAO-A, MAO-B,
and tryptophan hydroxylase in the dorsal raphé nucleus of
highly perseverative rats. Barlow et al. (2015) found no evidence
of significant differences in markers of DA and 5-HT function
in the DMS or MAO expression in the ventral tegmental area
of low- vs. high-perseverative rats; indicating that diminished
serotonergic tone (probably, at least via 5-HT2A receptor) in the
OFC may be an endophenotype that predisposes to behavioral
inflexibility and other forms of compulsive behavior (Barlow
et al., 2015).
Moreover, Lim et al. (2014) investigated mechanisms of
action of psychoactive drugs that modestly benefit the cognitive
performance in fragile X patients (the most common form
of inherited mental retardation); reporting that compounds
activating 5HT2B receptor (5HT2B) or dopamine (DA) subtype
1-like receptors (D1-Rs) and/or those inhibiting 5HT2A or
D2 receptors moderately enhance Ras-PI3K/PKB signaling
input, GluA1-dependent synaptic plasticity, and learning
in Fmr1 knockout mice (Lim et al., 2014). Unexpectedly,
combinations of these 5-HT and DA compounds at low doses
synergistically stimulate Ras-PI3K/PKB signal transduction
and GluA1-dependent synaptic plasticity and remarkably
restore normal learning in Fmr1 knockout mice without
causing anxiety-related side effects. Lim et al. (2014) suggest
that properly dosed and combined psychoactive drugs may
effectively treat the cognitive impairment associated with fragile
X syndrome. In addition, Htr2B−/− mice show deficits in
sensorimotor gating, selective attention, social interactions as
well as in learning and memory (i.e., fear conditioning and
novel object recognition: STM and LTM) (Pitychoutis et al.,
2015).
Regarding 5-HT2C receptor, Vimala et al. (2014) highlight
that epilepsy affects negatively cognitive function, producing
depression, anxiety, etc. Mentioning among other issues that
agomelatine is a novel antidepressant acting as melatonin MT1
and MT2 receptor agonist and 5-HT2C receptor antagonist;
producing reduction in the depolarization-evoked release
of glutamate, strong neuroprotective action and possible
antioxidant effects (Vimala et al., 2014); producing hippocampal
neuronal cell survival and neurogenesis, neuroprotective effect
in hippocampus and frontal cortex and the antioxidant potential
may contribute to the protective action of agomelatine against
epilepsy induced memory decline (Vimala et al., 2014). In
addition, Walker and Foley (2010) report that administration
of the 5-HT2C inverse agonist mianserin impaired autoshaped
operant response on day 2 than any other agent tested. In
addition, decreasing the length of the acquisition session to
1-h augmented the difficulty of the autoshaping task further
modulating the consolidation effects produced by the 5-HT2C
ligands (Walker and Foley, 2010). Moreover, Li et al. (2015b)
report that repeat exposition to 2.856 GHz microwaves
(averaging 5–30mW/cm2) affects spatial learning and
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TABLE 5 | 5HT3 receptor antagonist, neuroprotection.
Function/dysfunction Findings References
AD Tropisetron, a potent α7 nAChR agonist and 5-HT3 receptor antagonist, also bound to the ectodomain of
amyloid precursor protein. Furthermore, tropisetron promoted greater improvements in memory current AD
therapeutic drugs AD.
In addition, tropisetron represents an attractive potential therapeutic drug to delay or prevent MCI and AD.
This drug is also used for the treatment of chemotherapy-induced emesis
Hashimoto, 2015
Fakhfouri et al., 2014
Aβ rat model of AD in MWM - Tropisetron might have a neuroprotective effect; tropisetron attenuated Aβ-induced hippocampal
neuroinflammation
Hashimoto, 2015
Subtypes of 5-HT3 receptor Thompson, 2013
KO 5-HT3A receptor Loss of exercise-induced hippocampal neurogenesis and antidepressant effects, but not of learning
enhancement
Kondo et al., 2014
AD, Alzheimer’s disease; MCI, middle cognitive impairment; MWM, Morris water maze.
memory function, morphology structure of the hippocampus,
electroencephalogram (EEG) and neurotransmitter content
(amino acid and monoamine); including expression of 5-
HT1A 2A, and 2C receptors. Li et al. (2015b) demonstrated that
chronic exposure to microwave could induce dose-dependent
deficit of spatial learning and memory and inhibition of
brain electrical activity, the degeneration of hippocampus
neurons, and the disturbance of neurotransmitters; including
hippocampal and cortical expression of 5-HT1A and 5-HT2C
receptors.
Importantly, 5-HT2A/2B/2C receptors are useful detecting
learning and memory changes and drug effects. Aloyo et al.
(2009) remind us of inverse agonism at 5-HT2A and 5-HT2C
receptors.
5-HT3 Receptor
5-HT3 receptor antagonists (e.g., tropisetron, ondansetron) have
a long dated antiamnesic effects, including attenuation of age-
associated memory impairment (e.g., Costall and Naylor, 1992;
see also Shimizu et al., 2013). Recent evidence, from preclinical
studies suggests that the interaction between amyloid-β peptides
(Aβ) and the α7 nicotinic acetylcholine receptor (α7 nAChR)
(Hashimoto, 2015) (Table 5). And tropisetron is also a α7
nAChR agonist and 5-HT3 receptor antagonist; binding to
amyloid precursor protein and enhancing memory in AD
patients (Table 5). Importantly, 5-HT3 receptor antagonists have
been useful in treatments such as chemotherapy-induced emesis
to neuroprotection (Fakhfouri et al., 2014; Hashimoto, 2015).
Certainly, subtypes of 5-HT3 receptor exist (Thompson, 2013);
and their mechanisms are complex. For instance, Kozuska et al.
(2014) deal with the multiple salt bridges in the intracellular
domain of the 5HT3A receptor and these interactions increase
the overall rigidity of the receptor, stabilize its low conducting
state and affect the ligand cooperativity; suggesting that the
allosteric effects of these regions on the receptor may be involved
in a possible “reverse” allosteric modulation of 5HT3 receptor.
In addition, it should be noted that agonist- and antagonist-
induced up-regulation of surface 5-HT3A receptor (Morton et al.,
2015).
Moreover, Kondo et al. (2014) studied 5-HT3A receptor
subunit-deficient (htr3a-/-) mice revealing loss of exercise-
induced hippocampal neurogenesis and antidepressant effects,
but not of learning enhancement (Table 5). Kondo et al. (2014)
conclude that the 5-HT3 receptor is the critical target of 5-HT
action in the brain following exercise, being indispensable for
hippocampal neurogenesis and antidepressant effects induced by
exercise.
5-HT4 receptor
It should be noted that earlier evidence indicated that 5-HT4
receptor decreased in AD (see Eglen et al., 1995). Activation
of 5-HT4 receptor has pro-cognitive effects on memory tasks
(e.g., Bockaert et al., 2011; Peñas-Cazorla and Vilaró, 2014;
Ramirez et al., 2014; Claeysen et al., 2015). Notably, Madsen
et al. (2011) observe cerebral 5-HT4 receptor up-regulation
starts at a preclinical stage of dementia and it continues while
dementia is still at a mild stage and these authors speculate that
this upregulation may be a compensatory effect of decreased
levels of interstitial 5-HT, increase acetylcholine release or to
counteract Aβ accumulation and improved cognitive function.
Hippocampal 5-HT4 receptor expression correlates inversely
with human memory (Haarh et al., 2013; Table 6). Also, old rats
have decreased 5-HT4 receptor expression and poor memory
relative to adult (Table 6).
In addition, evidence suggests that serotonergic activity, via
5-HT4 receptors in hippocampal, striatum, and cortical areas,
mediates memory function and provides further evidence for a
complex and regionally specific regulation over 5-HT receptor
expression during memory formation (Manuel-Apolinar et al.,
2005).
Segu et al. (2010) report adaptive changes in cholinergic
systems, which may circumvent the absence of 5-HT4 receptor
to maintain long-term memory under baseline conditions. In
contrast, despite of adaptive mechanisms, the absence of 5-HT4
receptor aggravates scopolamine-induced memory impairments.
The mechanisms whereby 5-HT4 receptor mediates a tonic
influence on ChAT activity and muscarinic receptors remain
to be determined (Segu et al., 2010). Restivo et al. (2008)
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TABLE 6 | 5HT4 receptor.
Function/dysfunction Findings References
Memory Activation has promnesic effects in rodents and humans Haahr et al., 2013; Peñas-Cazorla and
Vilaró, 2014
Mechanisms in cognition Increased dendritic spines in the CA1 region of the hippocampus.
Neuronal activity and increased release of acetylcholine in the prefrontal cortex
and hippocampus. It is not synthesized in cholinergic cells
Pre-training SL65.0155 enhances olfactory memory discrimination, inducing hippocampal growth
dendritic spines; suggesting that selective 5-HT4 stimulation increases structural plasticity in
learning activated hippocampal circuits
Restivo et al., 2008; Marchetti et al.,
2011; Peñas-Cazorla and Vilaró, 2014
Changes with age Old rats decreased 5-HT4 expression and poor memory relative to adult Waeber et al., 1996; Manuel-Apolinar
et al., 2005; Marchetti et al., 2011
Memory Hippocampal 5-HT4 expression correlates inversely with memory in humans. Haahr et al., 2013
AD This receptor and β-amyloid protein are present in early stages of AD Madsen et al., 2011
AD, Alzheimer’s disease.
highlight that pharmacological modulation of synaptic efficacy is
a prominent target in the identification of promnesic compounds
and that pre-training administration of the 5-HT4 receptor
partial agonist SL65.0155 enhances olfactory discrimination
and potentiates learning-induced dendritic spine growth in the
mouse hippocampus; without affecting spine density in the
pseudo-trained mice and, by itself, it does not promote spine
growth. Likewise, the 5-HT4 receptor antagonist RS39604 prior
to SL65.0155 prevents both improved memory and additional
formation of spines; thus confirming the 5-HT4 receptor
specificity of the observed effects (Restivo et al., 2008); and these
authors conclude that 5-HT4 receptor stimulation selectively
increases experience-dependent structural plasticity in learning-
activated hippocampal circuits.
Marchetti et al. (2011) have also highlighted that in developing
rats as well as in rats ranging from 3 to 9 months of age,
significant modifications of 5-HT4 receptor expression have
been observed (for references see Marchetti et al., 2011).
These same authors propone that the poor memory formation
observed in aged rats (Marchetti et al., 2011). And corresponding
decreases in 5-HT4 receptor expression in brain areas (e.g.,
hippocampus, amygdala, etc.) involved in memory formation,
could explain improved memory, dendritic spines (Restivo et al.,
2008), neuronal excitability and release of the neurotransmitter
acetylcholine (Ach) (see Segu et al., 2010; Marchetti et al., 2011;
Peñas-Cazorla and Vilaró, 2014). Clearly, 5-HT4 receptor is
useful neural marker of dysfunctional and memory formation as
well as therapeutic target. Moreover, studying 5-HT expression
during memory formation is giving new fresh insights (e.g.,
Haahr et al., 2013). Importantly, Haahr et al. (2013) report that
hippocampal 5-HT4 receptor expression correlates inversely with
human memory performance.
5-HT5
As mentioned above, Cavallaro (2008) reported that passive
avoidance memory involves expression of several 5-HT
receptors, including 5-HT5A. 5-HT5 receptor occurs in brain
areas implicated in learning and memory. Post-training
administration of the 5-HT5A receptor antagonist SB-6995516
decreased CR during short-term (STM; 1.5-h; at 0.1mg/kg)
and long-term memory (LTM; 24-h; at 3.0mg/kg). Moreover,
considering that there are no selective 5-HT5A receptor agonists,
next, diverse doses of the serotonin precursor l-tryptophan
were studied during STM and LTM, showing that l-tryptophan
(5–100mg/kg) facilitated performance, particularly at 50mg/kg.
In interactions experiments, l-tryptophan (50mg/kg) attenuated
the impairment effect induced by SB-699551 (either 0.3 or
3.0mg/kg) (Gonzalez et al., 2013). All together this evidence
suggests that the blockade of 5-HT5A receptor appear to be able
to impair STM and LTM (24 h) in autoshaping task, while its
stimulation might facilitate it. Of course further investigation is
necessary, meanly with selective 5-HT5A compounds (Gonzalez
et al., 2013). Interestingly, Yamazaki et al. (2014, 2015) reported
that a 5-HT5A receptor antagonist ameliorates positive symptoms
and cognitive impairment in animal models of schizophrenia
and in aged rats and induced-amnesia. An analogous case is
observed regarding 5-HT1A partial agonists (see above).
Returning to 5-HT5 receptor, Karimi et al. (2013) report that
it has long been known that hippocampal spatial memory and
the ability to navigate through space are sexually dimorphic
traits among mammals, and numerous studies have shown
that these traits can be altered by means of sex hormone
manipulation. Male and female rat pups were injected with
estradiol and testosterone respectively, at early stage of their
lives to examine the effect of sex hormone manipulation on
mRNA expression of Slc9a4, Nr3c2, Htr5b, and Mas1; among
other results, these authors report that expressions of these genes
are strongly influenced by sex hormones in both the frontal
cortex and hippocampus, especially in male hippocampus, in
which expression of all genes were up-regulated. Htr5b was the
gene that was affected only in the males (Karimi et al., 2013).
Hence, considering the pharmacological evidence mentioned
above, probably learning and memory might be affected in these
animals.
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5-HT6 receptor
Diverse 5-HT6 receptor antagonists produce promnesic and/or
antiamnesic effects in conditions, such as memory formation,
age-related cognitive impairments; memory deficits in models
of diseases such as schizophrenia, PD and AD (e.g., King
et al., 2008; Claeysen et al., 2015). However, not all papers
report promnesic and/antiamnesic effects of 5-HT6 receptor
antagonists (e.g., Thur et al., 2014) (Table 7); probably related
to timing, drug and memory task used. Memory, aging,
and AD modify 5-HT6 receptors and signaling cascades;
and 5-HT6 drugs modulate memory, which is accompanied
with neural changes. Indeed, in an elegant work Eskenazi
et al. (2015) manipulated selectively overexpression of 5-HT6
receptor in either direct or indirect pathway striatal medium-
spiny neurons (dMSN and iMSN, respectively), revealing
that increased 5-HT6 receptor expression in iMSNs delays
instrumental learning and in DLS facilitates behavioral flexibility
after habitual responding. It should be noted that 5-HT6
receptor expression decreases during memory (e.g., Huerta-
Rivas et al., 2010; Ramirez et al., 2014). In addition, de Bruin
and Kruse (2015) suggest that cognition could be improved
by 5-HT6 receptor antagonists, by increasing the number of
NCAM PSA-immunoreactive neurons in the dendate gyrus,
inhibit mTOR and Fyn-tyrosine kinase and interact with
DARPP-32.
Notably, 5-HT6 receptor antagonists are, among, serotonergic
therapies for cognitive symptoms in AD (e.g., Ramirez et al.,
2014). Indeed, Wilkinson et al. (2014) report safety and efficacy
of idalopirdine, a 5-HT6 receptor antagonist, in patients with
moderate AD. In addition, 5-HT6 receptor is providing new
insights about plasticity (Dayer et al., 2015). For example, at early
stages of neuronal development, expression of 5-HT6 receptor
constitutively regulates the activity of the cyclin-dependent
kinase (Cdk) 5 and, through this mechanism, controls cellular
processes involved in circuit formation (e.g., neuronal migration,
neurite outgrowth). In addition, 5-HT6 receptor modulates
developmental targets, including Fyn, Jab1, and mammalian
target of rapamycin (mTOR). In therapeutic terms such as
blockade of pathological over-activation of the mTOR pathway
induced by early life insults in rodents and normalizes the
associated social and episodic memory deficits. It should be
noted that 5-HT6 receptor and Cdk5; and the latter mediates
neuronal differentiation (e.g., hippocampus, striatum) in an
agonist-independent manner (Seo and Tsai, 2014). In addition,
Ha et al. (2015) report that 5-HT6 receptor directly interacts
with SNX14 (protein-coupled receptors/regulators of G protein
signaling), which regulates internalization; degradation of 5-HT6
receptor and cAMP production. This finding might be related
to the evidence that 5-HT6 receptor agonists and antagonists
modulate cAMP production and improve memory formation
(e.g., Meneses et al., 2011c). We do not know yet why 5-
HT6 receptor agonists and antagonists (e.g., Woods et al.,
2012) may facilitate memory or may reverse amnesia in some
memory tasks. However, 5-HT6 receptor inverse agonist might
be useful (e.g., Hostetler et al., 2014; but see also Benhamú et al.,
2014).
TABLE 7 | 5-HT6 receptor.
Function/dysfunction Findings References
Memory/models of diseases Antagonism produce promnesic and/or antiamnesic effects, including memory formation,
age-related cognitive impairments; memory deficits in models for diseases such as
schizophrenia, Parkinson, and AD
Meneses et al., 2011a; Ramirez et al.,
2014; but always see Thur et al.,
2014
Memory, aging, and AD Modify 5-HT6 receptor and signaling cascades Ramirez et al., 2014
Expression 5-HT6 decreases during memory Huerta-Rivas et al., 2010; Ramirez
et al., 2014
Expression Overall, increased 5-HT6 receptor expression in iMSNs slowed instrumental learning and in
DLS facilitated behavioral flexibility after habitual responding
Eskenazi et al., 2015
Cognitive therapy Idalopirdine antagonist administration improves memory in patients with moderate AD Wilkinson et al., 2014; see also
Ramirez et al., 2014
Mechanisms Blocking this receptor decreases over-activation of mTOR when there are insults in early life
rodent deficits associated this normalize the social and episodic memory
Dayer et al., 2015
Signaling molecules Cdk5 activity regulated and controlled by this neuronal migration and neurite outgrowth.
Cdk5 modulates the activity of Fyn, Jab1 and mTOR
Dayer et al., 2015
SNX 14 is an endogenous negative regulator of 5-HT6 receptor, modulating its signaling and
trafficking Also, SNX 14 internalizes and degrades 5-HT 6 receptor
Ha et al., 2015
AD, Alzheimer’s disease; Cdk5, cyclin-dependent kinase; mTOR, mammalian target of rapamycin; dMSN, direct or indirect, iMSM pathway medium-spiny neurons.
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5-HT7 Receptor
Recently Nikiforuk (2015) is providing perspectives of 5-HT7
receptor in the search for treatments for CNS disorders: including
normal and dysfunctional serotonin-induced phase shifting of
the circadian rhythm control of memory as well as locomotor and
exploratory activity, anxiety, depression; and Guseva et al. (2014)
aboutmolecular mechanisms responsible for the 5-HT7 receptor-
mediated signaling. Gasbarri and Pompili (2014) noted that 5-
HT7 receptor antagonism might have antiamnesic effects (see
also Horisawa et al., 2013). Gasbarri et al. (2008) suggested that 5-
HT7 receptor blockade had procognitive effect, when the learning
task implicated a high degree of difficulty. Others report that 5-
HT7 receptor agonists facilitate memory and have antiamnesic
effects (Table 8); remaining clarifying why of the paradoxical
effects.
Notably, Saroja et al. (2014), highlight that although
evidence about monoamine receptor (MAR) biochemistry and
pharmacology in aging exists, work on MAR complexes rather
than subunits is limited; in consequence, MAR complexes in
hippocampi of three different age groups (3–12 and 18 months)
in mice and to link MAR changes to spatial memory retrieval in
the water maze were determine (Table 8). MAR complexes were
separated in order to show the pattern of dopamine and 5-HT1A
and 5-HT7 receptors and colocalizations (Saroja et al., 2014).
For instance, D1-D2 and 5-HT7 receptors containing receptor
complex levels decreased with age while 5-HT1A receptor-
containing complex was increasing. D1, 5-HT7, and 5-HT1A
receptor complex correlated with good retrieval memory in the
water maze; hence, individual monoamine receptors are linked
to spatial memory and are modulated by age. However, Beaudet
et al. (2015) mention that changes in the level of transcription of
the 5-HT7 receptor mRNA did not account for the age-related
difference observed at the protein level, at least in hippocampal
CA3 region; besides, 5-HT7 receptor might also be putatively
subjected, across aging, to modifications in their affinity or
to changes in their coupling to G-proteins or other signaling
TABLE 8 | 5-HT7 receptor.
Function/dysfunction Findings References
Brain development, autism, depression Contributes to networks during development and in the mature brain
remodel, thus participating in emotion and cognition
Ciranna and Catania, 2014; Guseva et al.,
2014; Volpicelli et al., 2014; Nikiforuk, 2015
Memory/amnesia Apparently 5-HT7 receptor agonists and antagonist might facilitate memory
formation and/or have anti-amnesic effects
e.g., Nikiforuk, 2015
Amnesia Antagonism might have antiamnesic effects Tajiri et al., 2012; Waters et al., 2012;
Horisawa et al., 2013; Nikiforuk et al., 2013;
Gasbarri and Pompili, 2014; Westrich et al.,
2015
Memory/amnesia Agonism has procognitive and/or antiamnesic effects Perez-García and Meneses, 2005;
Pérez-García et al., 2006; Costa et al., 2012;
Eriksson et al., 2012; Di Pilato et al., 2014;
Freret et al., 2014; Ruocco et al., 2014;
Meneses et al., 2015
Memory and mRNA expression Higher level of expression of 5-HT7 receptor mRNAs in autoshaping-trained
relative to untrained groups
Pérez-García et al., 2006
Memory time-course Progressive memory and mRNA 5-HT1A or 5-HT7 receptors expression
monotonically augments or declines in prefrontal cortex, hippocampus and
raphe nuclei, respectively
Perez-Garcia and Meneses, 2009
Aging and memory Hypothesis: a decreased expression of 5-HT7 receptor in CA3 hippocampal
could account for impairments of the shift between spatial strategies across
aging
Beaudet et al., 2015
Signaling Coupled to a Gs protein, stimulation activates the AC increased cAMP, in
addition, 5-HT7 is associated to G12; a small GTPase protein of the Rho
family. Gαs and Gα12are involved in the regulation of TrkB expression by
5-HT7, depending on the model of study
Guseva et al., 2014; Samarajeewa et al., 2014
Monoamine complex and memory D1, D2 and 5HT7 decreasing together with age, 5-HT1A receptors
containing complex MAR increase with age. The receptors MAR, 5-HT7,
5-HT7Aand D1, correlate with changes in spatial memory, which are
modulated by age
Saroja et al., 2014
MWM, Morris Water Maze; MAR, monoamine receptor complex (i.e., D1, D2, and 5-HT7 containing receptors).
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pathways. Notably, Beaudet et al. (2015) suggest that a decreased
expression of 5-HT7 receptor in CA3 hippocampal could account
for impairments of the shift between spatial strategies across
aging (Table 8).
Moreover, when the time-course (0–120 h) of autoshaped
CR is progressive; then mRNA 5-HT1A or 5-HT7 receptors
expression is monotonically augmented or decreased in
prefrontal cortex, hippocampus and raphe nuclei, respectively
(Perez-Garcia and Meneses, 2009). Hence, 5-HT1A and 5-HT7
receptors expression might be regulated by the level of memory
formation and to be brain areas dependent. Moreover, the cyclic
adenosine monophosphate (cAMP) is a second messenger and
a central component of intracellular signaling pathways that
regulate a wide range of biological functions, including memory
(e.g., Kandel, 2001). And progressive time-course of memory
formation in an autoshaping learning task (Pérez-García and
Meneses, 2008); shows that ex-vivo cAMP production from
trained and over-trained groups compared to untrained ones,
the former group had the highest levels of cAMP and the latter
rats showed increased production but less relative to trained
rats. Importantly these changes varied according with normal
memory or amnesia and brain areas; hence cAMP production
is important in the signaling case in mammalian memory
formation (Pérez-García and Meneses, 2008).
The above findings should be considered in the context
that apparently 5-HT7 receptor agonists and antagonist (e.g.,
Nikiforuk, 2015) might facilitate memory formation and/or
have anti-amnesic effects. Other interesting recent finding is
that according with Rojas et al. (2014) serotonin regulates
neurite outgrowth through 5-HT1A and 5-HT7 receptors in
cultured hippocampal neurons. Certainly, De Filippis et al.
(2015) highlight that promnesic effects of the 5-HT7 receptor
agonist LP-211 treatment strongly depend on the basal level
of performance. Notably, Ruocco et al. (2014) report that
5-HT7 receptor stimulation improves selective spatial attention
and produces permanent changes in several neural markers,
including expression of glutamatergic receptors and dopamine
transporter (DAT).
Very importantly, 5-HT7 receptor can form heterodimers
with 5-HT1A receptors both in-vitro and in-vivo (see Guseva
et al., 2014) and according with these authors, from the
functional point of view, heterodimerization decreases Gi-
protein coupling of 5-HT1A receptor and attenuates receptor-
mediate deactivation of G-protein-gated potassium (GIRK)
channels, without substantial changes in the coupling of 5-
HT7 receptor to the Gs-protein. Moreover, heterodimerization
significantly facilitated internalization of 5-HT1A receptor, while
internalization kinetics of 5-HT7 receptor was decelerated upon
heterodimerization (see Guseva et al., 2014).
Factors Responsible for Inconsistencies
among Laboratories
BOX 1 | Factors responsible for inconsistencies among laboratories.
Certainly, a number of factors might be produce similar results or be responsible
for some inconsistencies among laboratories studying memory; which are
complex and multi focal; which should provide an analytic framework offering
key clues. Indeed, analysis of memory should include behavioral tasks, type
of memory, the dynamic hierarchy of neural markers and brain areas involved
in memory formation (e.g., Euston et al., 2012; Eskenazi et al., 2015) vs. no
training, amnesia, anti-amnesic effects or forgetting (e.g., see below). Likewise,
the species and the nature of behavioral task (e.g., appetitively or aversively
motivated), curves of behavioral acquisition (i.e., multi-trial or two trials task)
or patterns of behavioral responses (progressive vs. all or none response),
cognitive demand (easy or difficult task), timing of drug administration
(pre-training, post-training or pretest) and kind of drug (e.g., agonist or
antagonist), protocols of training and testing together with neurobiological
markers (e.g., Duewer et al., 1995; Patton, 1995) accompanying mnemonic
processes deserve attention. Among the behavioral memory tasks available
(e.g., Peele and Vincent, 1989; Myhrer, 2003; Lynch, 2004); importantly, the
implementation of new instruments for measuring memory in behavioral tasks
assists in gaining deeper insight into learning and memory processes (e.g.,
Cook et al., 2004; Walker et al., 2011; Markou et al., 2013; Leger et al., 2014;
Wolf et al., 2014).
Neural Transporters, Memory, Forgetting and
Drugs
Notwithstanding neurotransmission systems are related to
memory formation, amnesia and/or therapeutic targets for
memory alterations, the role of transporters γ-aminobutyric
acid (GABA, GAT1), glutamate (neuronal glutamate transporter
excitatory amino acid carrier; EACC1), dopamine (DAT)
and serotonin (SERT) is poorly understood. Emerging evidence
indicates that memory formation (short- and long-termmemory;
STM and LTM, respectively) in a Pavlovian/instrumental
autoshaping (see Box 1) is associated to up-regulation of
prefrontal cortex GAT1 and EAAC1, striatal SERT, DAT and
EACC1; while, hippocampal EACC1, GAT1, and SERT are down-
regulated (Tellez et al., 2012a,b; Table 9; Figure 1). Moreover,
pharmacological analysis shows that methamphetamine
(METH)- induced amnesia down-regulated SERT, DAT,
EACC1, and GAT1 in hippocampus and the GAT1 in striatum;
no-changes are observed in prefrontal cortex. Fluoxetine
(antidepressant, 5-HT uptake inhibitor) improved memory
consolidation (particularly LTM), which is associated to DAT,
GAT1 (prefrontal cortex) up-regulation, but GAT1 (striatum)
and SERT (hippocampus) down-regulation. Fluoxetine plus
METH prevented amnesia, which was associated to DAT, EACC1
and GAT1 (prefrontal cortex), SERT and DAT (hippocampus)
and EACC1 or DAT (striatal) up-regulation.
Memory Formation/Forgetting and SERT
Expression
Forgetting in Pavlovian/instrumental autoshaping is associated
to up-regulation of GAT1 (PFC and HIP) and DAT (PFC)
while SERT (HIP) is down-regulated; no-changes are observed
in striatum (Table 9). Methamphetamine alone not affected
forgetting but up-regulates hippocampal DAT and EACC,
prefrontal cortex DAT and striatal GAT1 or EACC1. Fluoxetine
alone prevents forgetting, which is associated to striatal
GAT1 and hippocampal DAT up-regulation, but prefrontal
cortex GAT1 down-regulation. Fluoxetine plus METH prevent
forgetting, which is associated to hippocampal DAT, prefrontal
cortex SERT and striatal GAT1, DAT, or SERT up-regulation,
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BOX 2 | Autoshaping tasks.
Autoshaping memory tasks have been focus by several research groups (e.g., Brown and Jenkins, 1968; Myer and Hull, 1974; Atnip, 1977; Oscos et al., 1988; Bussey
et al., 1997, 2013; Lindner et al., 2003; Vanover et al., 2004; Ballaz et al., 2007; Rodriguez et al., 2008; Walker and Foley, 2010; Walker et al., 2011; Tomie et al., 2012;
Krynetskiy et al., 2013; Markou et al., 2013; Gallistel et al., 2014; Holland et al., 2014; Lesaint et al., 2014; Talpos et al., 2014; Eskenazi et al., 2015; Talpos and Shoaib,
2015; in several animal species (e.g., Wasserman, 1981) including humans (Wilcove and Miller, 1974; Pithers, 1985). According with Holland et al. (2014), “autoshaping”
or “sign-tracking” phenomenon has recently attracted considerable attention as a platform for studying individual differences in impulsivity, drug sensitization, and other
traits associated with vulnerability to drug addiction. Autoshaping has been also used for detecting effects induced by memory, amnesia, drugs, genetic variations,
aging and neural markers (e.g., Tomie et al., 2003, 2012; Vanover et al., 2004; Rodriguez et al., 2008; Fitzpatrick et al., 2013; Markou et al., 2013; Talpos et al., 2014).
Notably, autoshaping is an associative automatized learning task (see below), and during memory consolidation of Pavlovian/instrumental autoshaping learning task,
dentate gyrus, hippocampal CA1, basolateral amygdaloid nucleus and prefrontal cortex are require (see below). It should be noted that an important innovation, and
growingly popular method of assessing cognitive functions is the automated touchscreen platform (e.g., Abela et al., 2013; Talpos et al., 2014; Delotterie et al., 2015),
used for diverse cognitive tasks, comparable those in employ in human subjects (Horner et al., 2013), including autoshaping (e.g., Gallistel et al., 2014; Talpos et al.,
2014; Silverman et al., 2015).
Autoshaping learning tasks involve classical and instrumental conditioning (i.e., stimulus-stimulus and stimulus-responding conditioning). It should be mentioned that
long-lasting memories are most efficiently formed by multiple training sessions separated by appropriately timed intervals. Autoshaping meets this criterion and
it allows modeling of behavioral situations requiring integration of information obtained from sign- and goal-tracking settings; representing memory of self-taught
settings (Meneses, 2013, 2014). Certainly, autoshaping tasks (Pavlovian or instrumental; and Pavlovian/instrumental may produce initial modest and/or variable levels
of conditioned responses (CR). Importantly, memory formation, amnesia and forgetting in Pavlovian/instrumental paradigms are accompanied by changes in neural
markers, including 5-HT, glutamate, dopamine, and GABA transporters expression levels (Tomie et al., 2003; Tellez et al., 2012a,b), 5-HT receptor expression and
cAMP production (Meneses, 2013). Certainly, forgetting as therapeutic targets for dysfunctional memory it has been little explored. As above mentioned, similar results,
including pharmacological and neurobiological changes to those reported in autoshaping have been described in other memory behavioral tasks (for review see King
et al., 2008; Marcos et al., 2008; Da Silva Costa-Aze et al., 2012; Reichel et al., 2012; Woods et al., 2012; Haahr et al., 2013; Freret et al., 2014; Nasehi et al., 2014b;
Seyedabadi et al., 2014; Subramaniyan et al., 2014; Wilkinson et al., 2014; Delotterie et al., 2015; Sase et al., 2015; Westrich et al., 2015).
Behavioral parameters during STM and LTM
In addition to measuring CR in autoshaping, head-pokes (HP) during each training/testing session and head-pokes during CS (HP-CS) have recorded. These parameters
provide information about exploration activity (HP) and food- intake motivation (Tellez et al., 2012a). For instance, as CR becomes progressive, HP-CS provides
information on the association of CS-US and CR-US.
Maximum level of CR
It should be noted that as animals present different levels of CR, these values are normalized and the maximal CR level attained for each rat at 48 h is considered as
100% of performance. This value is then used to calculate the proportion or percentage of CR observed at 1.5, 24, and 216 h and the data of 1.5 h and 24 h are used
as illustration; and multiple comparisons, including memory, forgetting, time vs. treatments for all behavioral parameters (Meneses and Tellez, 2015).
Memory, amnesia and forgetting and neural transporters analysis
As already mentioned autoshaping procedures produce variable levels of CR and a number of laboratories have been using autoshaping. It should be noted that,
reproducibility among studies is important and expected that to vary (e.g., Marcus, 2014).
but prefrontal cortex GAT1 down-regulation. Together these
results show that forgetting provokes primarily hippocampal and
prefrontal cortex transporters changes; it represents a cognitive
process hardly modifiable and its prevention could causes
different transporters expression patterns. Notably, together the
results suggest that: (1) memory formation, amnesia and anti-
amnesic effects are associated to specific patterns of transporters
expression; (2) STM and LTM, forgetting and anti-forgetting
effects are associated to specific patters of transporters expression
and brain areas; (3) amnesia and forgetting affect different brain
areas and produce differential patters of transporter expression.
Hence, in pharmacological and neuroanatomical terms, amnesia
and forgetting differ.
Neural Transporters and Brain Functions and
Dysfunctions
It should be noted that neural transporters regulate intra-
synaptic levels of neurotransmitter, which allows a global
picture of synapses. Moreover, diverse evidence indicates that
memory formation, forgetting, amnesia, and/or anti-amnesic
effects can also be modulated by changes in the expression of
neurotransmitter transporters (e.g., Schmitt and Hiemke, 2002;
Chen et al., 2011; Reichel et al., 2012; Yang et al., 2013). Hence, a
brief overview of evidence involving GAT1, EAAT1, SERT, and
DAT as well other neurobiological markers regarding memory
and other cerebral functions is include.
GAT 1
Attention deficit/hyperactivity disorder (ADHD) is featured by
hyperactivity, impaired sustained attention, impulsivity, and
usually varying degrees of dysfunctional learning and memory
(see also Meneses et al., 2011b) and motor incoordination (Yang
et al., 2013). Importantly, Yang et al. (2013) report that GAT1
gene knockout (KO) mouse (GAT1−/−) is hyperactive and
exhibit impaired memory performance (Morris water maze).
KO GAT1 mice have low levels of attentional focusing and
increased impulsivity; the hyperactivity in these KO mice is
reduced by both methylphenidate and amphetamine; Yang et al.
(2013) suggest that GAT1 KO mouse is a new animal model
for ADHD studying and GAT1 may be a new target to treat
ADHD. Schmitt and Hiemke (2002) note that GABA is cleaved
from the synaptic cleft by uptake (see Hu and Quick, 2008),
via specific transporters and inhibition of such transporters
increases the effectiveness of physiologically released GABA.
Increased GABAergic neurotransmission has an impact on
learning and memory. Indeed, tiagabine, a GABA-transporter
inhibitor, impaired learning (Morris water-maze) and retrieval
(only at the probe trial; Schmitt and Hiemke, 2002). But,
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TABLE 9 | Neural transporters during STM and LTM, amnesia (methamphetamine), forgetting, (fluoxetine) improved LTM, (fluoxetine) anti-forgetting
effects and anti-amnesic (fluoxetine plus methamphetamine) effects.
Cognitive process Neural transporters expression of transporters in brain areas References Tellez et al., 2012a,b
STM and LTM Up-regulation of PFC GAT1 and EAAC1, striatal SERT, DAT and EACC1; while, HIP EACC1, GAT1 and SERT are down-regulated
Amnesia Down-regulated SERT, DAT, EACC1 and GAT1 in HIP the GAT1 in striatum; no-changes are observed in PFC
Forgetting Up-regulation of GAT1 (PFC and HIP) and DAT (PFC) while SERT (HIP) is down-regulated; no-changes are observed in striatum
Improved LTM DAT, GAT1 (PFC up-regulation), but GAT1 (striatum) and SERT (HIP) down-regulation
Anti-forgetting effects striatal GAT1 and HIP DAT up-regulation, but PFC GAT1 down-regulation
Anti-amnesic effects DAT, EACC1 and GAT1 (PFC), SERT and DAT (HIP) and EACC1 or DAT (striatal) up-regulation
STM, short-termmemory; LTM, long-termmemory; GAT1, GABA transporter 1; DAT, dopamine transporter; SERT, serotonin transporter; EACC1, glutamate transporter 1; PFC, prefrontal
cortex; HIP, hippocampus.
A B
FIGURE 1 | Schematic representation of changes with Western
blot analysis of neural transporters in prefrontal cortex,
hippocampus and striatum during memory formation and
temporal-course of forgetting. Strong color refers to up-regulation,
slight color refers to down-regulation. GAT1, GABA transporter 1;
EAAC1, neuronal glutamate transporter excitatory amino acid carrier-1;
DAT, dopamine transporter SERT, serotonin transporter (modified from
Tellez et al., 2010, 2012a,b).
Sałat et al. (2015) note that tiagabine slightly decreased
memory but did not augment that induced by scopolamine.
According with Shi et al. (2012), homozygous GAT1(−/−)
mice exhibit impaired hippocampus-dependent learning and
memory; and they evaluated the impact of endogenous reduced
GABA reuptake on cognitive behaviors. Learning and memory
of heterozygous GAT1(+/−) mice was determined in passive
avoidance and Morris water maze; showing that GAT1(+/−)
mice displayed increased learning and memory, decreased
anxiety-like behaviors, and highest synaptic plasticity relative
to wild-type and homozygous GAT1(−/−) mice; and authors
conclude that amoderate reduction in GAT1 activity is associated
to learning and memory facilitation (Shi et al., 2012); which is
consistent, in part, with GAT1 reduced and increased expression
in autoshaping amnesia, forgetting and improved memory as
well as anti-amnesic and anti-forgetting effects (see Table 10). In
addition, Pang et al. (2011) testing the GABAergic immunotoxin;
GAT1-saporin (GAT1-SAP), report no alterations in spatial
reference memory. But GAT1-SAP impaired the platform
location in a delayed match to position test (changing daily
the platform location). In the active avoidance task, intraseptal
GAT1-SAP impaired extinction but not acquisition (Pang et al.,
2011). In contrast, GAT1-Saporin into themedial septum/vertical
limb of the diagonal band (MS/VDB) spared mnemonic function
and use of environmental cues; however, self-movement cue
processing was compromised (Köppen et al., 2013).
EAAT1
According with Chen et al. (2011), an imbalance of
neurotransmitters (e.g., glutamate, acetylcholine, dopamine, and
serotonin) has been proposed as the neurobiological basis of
behavioral symptoms of AD, hence they are hypothesizing that
altered reuptake of neurotransmitters by vesicular glutamate
transporters (VGLUTs), excitatory amino acid transporters
(EAATs), the vesicular acetylcholine transporter (VAChT),
SERT or DAT. Examining protein and mRNA levels of
these transporters in post-mortem prefrontal cortex from
patients and matched non-AD controls, Chen et al. (2011)
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TABLE 10 | GABA transporter GAT1.
Function/dysfunction Findings References
GAT1 KO mice and ADHD Hyperactive behavior and memory dysfunctions in the MWM, also have low levels of attention and
increased impulsivity
Yang et al., 2013
GABA-transporter inhibitor Tiagabine, in the MWM, compared to saline treated rats, impaired learning during the acquisition trials.
And retrieval only at the probe trial
Schmitt and Hiemke, 2002
GAT1(−/−) KO mice Impaired hippocampus-dependent learning and memory (MWM, PA) Shi et al., 2012
GABAergic immunotoxin:
GAT1-saporin (GAT1-SAP)
Intraseptal impaired a delayed match to position task and extinction of avoidance without altering
acquisition of WMWM, active avoidance acquisition or open field behavior. Also, animals were slower
to update changes to previous contingencies
Pang et al., 2011; but see
Köppen et al., 2013
GAT1(+/−) mice Increased learning and memory, decreased anxiety-like behaviors, and highest synaptic plasticity
compared with wild-type and homozygous
GAT1(−/−) mice
Shi et al., 2012
ADHD, attention deficit and hyperactivity disorder; KO, knock out; MWM, Morris water maze; PA, passive avoidance.
TABLE 11 | Glutamate transporter 1 and markers.
Function/dysfunction Findings References
Glutamate and AD Reduced mRNA levels of VGLUTs, EAAT1-3 proteins Chen et al., 2011
MDMA Improved expression of GluR2 receptor, mGluR1, mGluR5, NR1, NR2A, NR2B and EAAT1,
EAAT2-2 transporters. Increased mRNA levels of GluR3, NR2A and NR2B in caudate putamen.




Mild stress model induced Mice heterozygous (+/− VGLUT1) VGLUT1 decrease expression relative to wild mice:
dysfunctions in recognition memory (recognition new object); anhedonia (sucrose intake),
hopelessness (forced swimming), anxiety (elevated plus maze)
Garcia-Garcia et al., 2009
Glutamate transporter 1 and training The hippocampal levels of GLT-1 complex are parallel to training in the memory multiple T-maze test Heo et al., 2012
AD, Alzheimer’s disease; VGLUTs, Vesicular glutamate transporters; MDMA, methylenedioxymethamphetamine.
found that protein and mRNA levels of VGLUTs, EAAT1-3,
VAChT, and SERT are reduced in AD, without changing DAT
(Table 11). Chen et al. (2011) conclude that the reduced VAChT
expression could contribute to cholinergic deficit in AD and
altered neurotransmitter transporters could contribute to the
pathophysiology of AD; which are potential targets for therapy
(Chen et al., 2011).
Likewise, Kindlundh-Högberg et al. (2010) investigated the
effect of intermittent 3,4-methylenedioxy-metamphetamine
(MDMA; ecstasy) administration upon gene-transcript
expression of the glutamate transporters (EAAT1, EAAT2-
1, EAAT2-2), glutamate receptor subunits of AMPA (GluR1,
GluR2, GluR3), glutamate receptor subunits of NMDA (NR1,
NR2A, and NR2B), and metabotropic glutamate receptors
(mGluR1, mGluR2, mGluR3, mGluR5); showing increased
cortical expression of GluR2, mGluR1, mGluR5, NR1, NR2A,
NR2B, EAAT1, and EAAT2-2 (Kindlundh-Högberg et al., 2010).
In the caudate putamen, mRNA levels of GluR3, NR2A, and
NR2B receptor subunits are increased; in contrast, GluR1
is reduced in the hippocampus but in the hypothalamus
GluR1, GluR3, mGluR1, and mGluR3 expression is increased
(Kindlundh-Högberg et al., 2010; see also Carmona et al., 2009);
concluding that repeated MDMA administration is associated
with changes in gene-transcript expressions of glutamatergic
NMDA and AMPA receptor subunits, metabotropic receptors
and transporters in brain areas mediating learning and memory
(Kindlundh-Högberg et al., 2010). In addition, decreased
expression of vesicular glutamate transporter 1 (VGLUT1+/−)
respect to wild-type (WT) mice occur with chronic mild stress
(CMS)-induced, affecting several functions and impairing
recognition memory. In addition, Heo et al. (2012) detect
hippocampal glutamate transporter 1 (GLT-1) complex
expression during training and memory in the Multiple T-maze.
SERT
Reichel et al. (2012) report that control rats spent more time
interacting with the objects in the changed locations. In
contrast, contingent or non-contingent methamphetamine
(meth) disrupted object-in-place (OIP) task performance
as seen by similar amounts of time spent with all objects,
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regardless of location. While only acute meth binge produced
signs of neurotoxicity, both meth regimens decreased
SERT in the perirhinal cortex and hippocampus. Only
meth self-administration resulted in a selective decrease in
NET. Meth-induced changes in SERT function in the OIP
circuitry may underlie memory deficits independently of overt
neurotoxic effects (Reichel et al., 2012). It should be noted
that SERT is reduced in AD (Chen et al., 2011; Claeysen et al.,
2015).
Parrott (2013) highlights that decreased SERT (hippocampus,
parietal cortex, and prefrontal cortex expression) in abstinent
Ecstasy/MDMA users is associated to dysfunctional declarative
and prospective memory. Even the children of mothers who
take Ecstasy/MDMA during pregnancy have psychomotor
impairments (Parrott, 2013). In addition, Thomasius et al. (2006)
report reduced SERT expression, which might be a transient
effect of heavy ecstasy use, since it partially recovered as the
users reduced their MDMA use; though this parameter may
not necessarily be a valid indicator of the number or integrity
of serotonergic neurons. Importantly, ex-ecstasy users’ verbal
memory show no sign of improvement even after over 2.5
years of abstinence and thus may represent persistent functional
consequences of MDMA neurotoxicity; alternative causes such
as pre-existing group differences cannot be excluded (Thomasius
et al., 2006). In addition, AD and drugs of abuse like d-
methamphetamine (METH) or MDMA have been associated
to decrements in the SERT expression and memory deficits;
thus supporting the notion that the SERT plays a key role in
both normal and pathological states (e.g., Line et al., 2014).
Particularly, the s allele of the polymorphic regulatory region of
the SERT or 5-HTT gene promoter is associated with reduced
5-HTT expression and vulnerability to psychiatric disorders,
including anxiety and depression. Moreover, the l allele increases
5-HTT expression and is generally considered protective (Line
et al., 2014). However, Line et al. (2014) suggest that 5-HTT
over-expression results in a reduced sensitivity to both positive
and negative reinforcers, and produces some maladaptive effects,
supporting recent suggestions that l allele homozygosity may
TABLE 12 | Serotonin transporter SERT.
Function/dysfunction Findings References
Methamphetamine Memory deficits and decreased SERT function in perirhinal cortex and hippocampus Reichel et al., 2012
MDMA (ecstasy) During abstinence memory deficits and decreased SERT in hippocampus, parietal cortex and
prefrontal cortex
Parrott, 2013
MDMA ex-users Verbal memory dysfunction even after 2.5 years of abstinence Thomasius et al., 2006
AD Decreased SERT Chen et al., 2011
5-HT re-uptake inhibition In healthy individuals and aged transgenic AD mice model (APP/PS1 plaque-bearing mice), citalopram
decreased Aβ in brain interstitial fluid in a dose-dependent manner
Sheline et al., 2014a,b
5-HT uptake inhibitor or SERT(−/−)
KO mice
Pharmacological or genetic inactivation of the serotonin transporter improves reversal learning in mice Brigman et al., 2010
Expression Overexpression of SERT reduces sensitivity to both positive and negative reinforcers evidence in CER
and the T-maze; this overexpression is maladaptive effects, suggesting that the homozygous allele/can
cause disabling psychiatric features
Line et al., 2014
Expression Increased 5-HTT expression reduces negative cognitive bias for stimuli with uncertain outcomes McHugh et al., 2015
AD, Alzheimer’s disease; MDMA, methylenedioxymethamphetamine; CER, conditioned emotional response.
TABLE 13 | Dopamine transporter DAT.
Function/dysfuntion Findings References
Cognition Variations in DAT1 influence the improvement of working memory in preschool
children after cognitive training
Söderqvist et al., 2012
Dopamine inhibition Modafinil is dopamine inhibitor can improve cognition in people with mental disorders
who use substances abuse
Mereu et al., 2013
Modulated DAT expression in animal model of ADHD Improved selective spatial attention Ruocco et al., 2014
ADHD, attention deficit and hyperactivity disorder.
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be a potential risk factor for disabling psychiatric traits (Line
et al., 2014). In contrast, increased 5-HTT expression reduces
negative cognitive bias for stimuli with uncertain outcomes
(McHugh et al., 2015). And Brigman et al. (2010) report
that fluoxetine-treated C57BL/6J mice made fewer errors than
controls during the early phase of learning reversal when
perseverative behavior is relatively high and 5-HTT null mice
made fewer errors than controls in completing the reversal
task (Table 12). And these authors suggest that inactivating
5-HTT improves reversal learning, which is relevant for the
pathophysiology and treatment of neuropsychiatric disorders
characterized by executive dysfunction (Brigman et al., 2010) and
possibly post-traumatic stress disorder.
Certainly, SERT is providing useful information as neural
marker and therapeutic target. For instance, Wallace et al.
(2014) report that vortioxetine, a novel, multimodal-acting
antidepressant, is a 5-HT3, 5-HT7, and 5-HT1D receptor
antagonist, a 5-HT1B receptor partial agonist, a 5-HT1A receptor
agonist, and inhibits the 5-HT transporter. This drug changes
the expression of multiple genes involved in neuronal plasticity
by antidepressant treatment, which is associated with improved
cognitive function and a reduction in depression-like behavior in
middle-aged mice (Li et al., 2015c).
Hence, the SERT expression seems to be a reliable neural
marker related to memory mechanisms, its alterations and
potential treatment (Meneses, 2013). Resulting crucial
determining the pharmacological, neural and molecular
mechanisms associated to these changes and therapeutic targets.
For instance, Sheline et al. (2014a) report that serotonin signaling
suppresses generation of amyloid-β (Aβ) in-vitro and in animal
models of AD and healthy individuals. In fact, in an aged
transgenic AD mouse model the antidepressant citalopram
(5-HT uptake inhibitor) in dose-dependent manner decreased
Aβ in cerebrospinal fluid, suggesting AD prevention trials
(Sheline et al., 2014a,b).
DAT
According with Mereu et al. (2013), modafinil (MOD) and
its R-enantiomer (R-MOD) are used for narcolepsy and sleep
disorders; and also employed, off-label used as cognitive
enhancers in individuals with mental disorders, including
substance abusers that demonstrate impaired cognitive function.
Their mechanisms of action include inhibition of dopamine (DA)
reuptake via the DAT in diverse brain areas (Mereu et al., 2013;
Table 13). Importantly, memantine (MEM), a dual antagonist of
NMDA and alpha7 receptors, is neuroprotector against MDMA
in rats, and it also prevents MDMA effect on SERT functionality
and METH effect on DAT (Escubedo et al., 2009). Moreover,
Söderqvist et al. (2012) have noted that dopamine plays an
important role not only in dysfunctional working memory (WM)
but also for improving it, including variation in DAT1, improving
WM and fluid intelligence in preschool-age children following
cognitive training; concluding with the role of dopamine in
determining cognitive plasticity (Söderqvist et al., 2012). Ruocco
et al. (2014) report that 5-HT7 receptor stimulation (low doses)
was associated to among other findings reduced horizontal
activity and (at higher dose) increased selective spatial attention,
the DAT levels were decreased (low dose), and modulated
expression of NMDA receptors.
It should be noted that, before the perspective of the absence of
effective treatments for dysfunctional memory and regardless the
mechanisms; environmental interventions and exercise (physical
and cognitive) seem offer feasible approaches (e.g., Mora, 2013;
Mo et al., 2015).
Conclusions
Of course if the above findings are replicated over time, across
countries and in different experimental settings, they might
provide insights about serotonin and other neurotransmission
systems presenting convergent changes in diverse neural
markers and signaling; thus, allowing the study of different brain
functions and dysfunctions, including memory. Hence, diverse
approaches might support the translatability of using neural
markers and cerebral functions and dysfunctions (e.g., memory
formation, AD, MCI). Likewise, hypothesis and theories (e.g.,
Borroto-Escuela et al., 2015) might provide appropriate limits
and perspectives of the diversity of evidence. Certainly, at least,
5-HT1A, 5-HT4, 5-HT5, 5-HT6, and 5-HT7 receptors as well as
SERT seem to be useful as neural markers and therapeutic targets.
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